The firm values the market at $34.03 billion in 2026 and expects oral semaglutide to grow fastest, citing early prescription numbers for the Wegovy pill.
Recap by typeshit. Full story at Precedence Research.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
A short TikTok on storing mixed peptide vials. It gives no source or details, and the handling advice is unverified.
Andrew Huberman and neuroscientist Scott Kanoski cover how food choices affect memory and cravings, with early chapters on natural GLP-1 and the drugs.
Loading…